Articles related to Hematology/Oncology

Under Dr. Laurie Glimcher’s leadership, Dana-Farber Cancer Institute is embarking on a transformative journey with the creation of a new, dedicated cancer hospital, promising a future of specialized care and improved patient experiences in oncology.

Explore the latest findings on vibecotamab’s potential in R/R AML treatment, revealing promising results with an optimized dosing regimen that mitigates cytokine response syndrome while improving patient outcomes.

The acquisition of radiation oncology centers amid bankruptcy proceedings highlights the critical need for seamless transitions to uphold patient care standards.

Explore the recent FDA approval of biweekly teclistamab dosing for multiple myeloma, a significant stride in offering personalized treatment schedules that cater to patient and clinician needs.

Exa-cel’s success in the CLIMB THAL-111 trial represents a transformative approach to treating β-thalassemia, eliminating dependency on transfusions and underscoring the potential of gene editing in hematological disorders.

This innovative device can transform breast cancer screening by providing a rapid, affordable, and non-invasive diagnostic solution, particularly beneficial in regions with limited access to traditional screening methods.